SOST and type 2 diabetes mellitus: Sclerostin is predominantly developed by osteocytes and inhibits osteoblast differentiation and bone-forming by antagonising the canonical Wnt signalling pathway by binding 5/6 receptor-related protein to receptor receptors with low-density lipoprotein [16]. Elevated serum sclerostin concentrations are correlated with prevalent vertebral fractures in patients with T2DM irrespective of BMD and bone turnover factors [8].